 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LYRA's total volume now sits at 2M. The +0.16% price change was insignificant, leaving IBM's price at $6.23...

The volume for Lyra Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 516% of the 65-Day Volume Moving Average

This indicator may be signaling that LYRA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Lyra Therapeutics (LYRA, $6.13) entered Downtrend as Momentum indicator drops below 0 level on Mar 26, 2024

LYRA's total volume now sits at 700.8K. The +0.99% average daily price change was insignificant these 3 days, leaving LYRA's price at $6.13...

The volume for Lyra Therapeutics stock increased for three consecutive days, resulting in a record-breaking daily growth of 187% of the 65-Day Volume Moving Average

LYRA Meets Analyst Expectations for Earnings Per Share, Reveals Full Year and Q4 2023 FinancialsRelated Stocks: LYRA...

Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Lyra Therapeutics files $300M mixed securities shelf

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
LYRA stock results show that Lyra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth...

LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023

Lyra Therapeutics reports Q4 results

-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc...

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics, Inc. (NASDAQ:LYRA  Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 29th, there was short interest...

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Short Interest Down 13.6% in February

This is a signal that LYRA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Lyra Therapeutics (LYRA, $5.71) RSI Indicator left the overbought zone on March 14, 2024

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Volume (M)	199,801.00
52-Wk High	$6.79
52-Wk Low	$1.93

LYRA Lyra Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals